Oxford BioTherapeutics Ltd   Report issue

For profit Phase 1
Founded: Oxton United Kingdom (2004)

Organization Overview

First Clinical Trial
2019
NCT04064359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Oxford BioTherapeutics Ltd

Active Ingredients

Drugs in Phase 1 Trials (1)

obt076 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1